Cardiology and Cardiovascular Research

| Peer-Reviewed |

The Association Between Systemic Hypertension and Chronic HCV-4 Infection

Received: 03 March 2017    Accepted: 27 March 2017    Published: 15 April 2017
Views:       Downloads:

Share This Article

Abstract

Patients with chronic hepatitis C virus infection are more likely to have systemic hypertension, in addition to insulin resistance and diabetes. The present study aimed to evaluate the association between systemic hypertension and chronic HCV-4 infection among Egyptian patients. This cross-sectional study evaluated the existence of systemic hypertension among one thousand adult Egyptian subjects (500 patients with chronic HCV-4 infection versus 500 non infected subjects who served as a control group). Prevalence of systemic hypertension was significantly higher among patients with chronic HCV-4 infection (38.8%) than among the controls (21.8%) (P=0.001). 30.3% of all hypertensive patients were not aware of their illness; the rate of non-awareness among hypertensive patients with chronic HCV-4 infection was 22.68% while that of non infected subjects was 44.04% (p < 0.05). A statistically significant higher rate of systemic hypertension was found among diabetic patients. In conclusion, significant association exists between chronic HCV-4 infection and systemic hypertension especially among diabetic patients. Patients with chronic HCV infection are more aware of their systemic hypertension than non infected subjects.

DOI 10.11648/j.ccr.20170102.12
Published in Cardiology and Cardiovascular Research (Volume 1, Issue 2, April 2017)
Page(s) 32-38
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Hypertension, Hepatitis C-4, Diabetes

References
[1] Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and liver fibrosis. Gastroenterology 2008; 134: 416-423.
[2] Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
[3] Adinolfi LE, Durante-Mangoni E, Zampino R, et al. Review article: hepatitis C virus-associates steatosis – pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005; 22 [2]: 52-55.
[4] Lecube A, Hernandez C, Simó R, et al. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2189-2195.
[5] Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
[6] Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core Protein inhibits microsomal triglyceride transfer protein activity and Very low density lipoprotein secretion: a model of viral – related steatosis. FASEB J 2002; 16: 185-194.
[7] Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138: 932–41, e 931–3.
[8] Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 [2]: 3–12.
[9] Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–41.
[10] Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225–32.
[11] Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894–900.
[12] Younossi Z. M., Stepanova M., Nader F., et al. Associations of Chronic Hepatitis C With Metabolic and Cardiac Outcomes. Aliment Pharmacol Ther. 2013; 37 [6]: 647-652.
[13] Maruyama S, Koda M, Oyake N, et al. Myocardial injury in patients with chronic hepatitis C infection. J Viral Hepat 2013; 58 (1): 11-5.
[14] Demir M, Demir C. Effect of hepatitis C virus infection on the left ventricular systolic and diastolic functions. South Med J 2011; 4: 425–32.
[15] Forde KA, Haynes K, Troxel AB, et al. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat 2012; 19: 271–7.
[16] Kamal M. and Nasser A. Hepatitis C Genotype 4: What We Know and What We Don’t Yet Know. Hepatology 2008; 47: 1371-1383.
[17] American Diabetes Association, Standards of Medical Care in Diabetes—2011. Diabetes Care 2011, 34 [1]: S11-S61.
[18] National Center for Health Statistics. National Health and Nutrition Examination Survey III: Data Collection Forms. Hyattsville, Md: National Center for Health Statistics; 1991.
[19] Frohlich ED, Grimm C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometer. Hypertension. 1988; 11: 210 A-222 A.
[20] Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993; 153: 154-183.
[21] Working Group on Primary Prevention of Hypertension. Report of the National High Blood Pressure Education Program Working Group on Primary Prevention of Hypertension. Arch Intern Med. 1993; 153: 186-208.
[22] Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9: 331-338.
[23] Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761.
[24] Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report, 2007. Available at .
[25] Kim WR: The burden of hepatitis C in the United States. Hepatology 2002, 36 [1]: S30-S34.
[26] Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221: 496–502.
[27] Ibrahim M. M., Rizk H., Appel L. J., et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project [NHP]. NHP Investigative Team. Hyperteion 1995; 26: 886-890.
[28] Azza Sarry El-Din, Moushira Erfan, Wafaa A. Kandeel, et al. Prevalence of Pre-hypertension and Hypertension in a sample of Egyptian Adults and its Relation to Obesity. Australian Journal of Basic and Applied Sciences 2012; 6 [13]: 481-489.
[29] Boddi M, Abbate R, Chellini B, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis. 2007; 39 [1] S 55-60.
[30] Chobanian A. V., Bakris G. L., Black H. R., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
Author Information
  • Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

  • Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

  • Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

  • Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

  • Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Cite This Article
  • APA Style

    Hany Awadallah, Ayman Mortada, Reham Ezzat Al Swaff, Ahmed Jomaa, Fatma Ali-Eldin. (2017). The Association Between Systemic Hypertension and Chronic HCV-4 Infection. Cardiology and Cardiovascular Research, 1(2), 32-38. https://doi.org/10.11648/j.ccr.20170102.12

    Copy | Download

    ACS Style

    Hany Awadallah; Ayman Mortada; Reham Ezzat Al Swaff; Ahmed Jomaa; Fatma Ali-Eldin. The Association Between Systemic Hypertension and Chronic HCV-4 Infection. Cardiol. Cardiovasc. Res. 2017, 1(2), 32-38. doi: 10.11648/j.ccr.20170102.12

    Copy | Download

    AMA Style

    Hany Awadallah, Ayman Mortada, Reham Ezzat Al Swaff, Ahmed Jomaa, Fatma Ali-Eldin. The Association Between Systemic Hypertension and Chronic HCV-4 Infection. Cardiol Cardiovasc Res. 2017;1(2):32-38. doi: 10.11648/j.ccr.20170102.12

    Copy | Download

  • @article{10.11648/j.ccr.20170102.12,
      author = {Hany Awadallah and Ayman Mortada and Reham Ezzat Al Swaff and Ahmed Jomaa and Fatma Ali-Eldin},
      title = {The Association Between Systemic Hypertension and Chronic HCV-4 Infection},
      journal = {Cardiology and Cardiovascular Research},
      volume = {1},
      number = {2},
      pages = {32-38},
      doi = {10.11648/j.ccr.20170102.12},
      url = {https://doi.org/10.11648/j.ccr.20170102.12},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ccr.20170102.12},
      abstract = {Patients with chronic hepatitis C virus infection are more likely to have systemic hypertension, in addition to insulin resistance and diabetes. The present study aimed to evaluate the association between systemic hypertension and chronic HCV-4 infection among Egyptian patients. This cross-sectional study evaluated the existence of systemic hypertension among one thousand adult Egyptian subjects (500 patients with chronic HCV-4 infection versus 500 non infected subjects who served as a control group). Prevalence of systemic hypertension was significantly higher among patients with chronic HCV-4 infection (38.8%) than among the controls (21.8%) (P=0.001). 30.3% of all hypertensive patients were not aware of their illness; the rate of non-awareness among hypertensive patients with chronic HCV-4 infection was 22.68% while that of non infected subjects was 44.04% (p < 0.05). A statistically significant higher rate of systemic hypertension was found among diabetic patients. In conclusion, significant association exists between chronic HCV-4 infection and systemic hypertension especially among diabetic patients. Patients with chronic HCV infection are more aware of their systemic hypertension than non infected subjects.},
     year = {2017}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Association Between Systemic Hypertension and Chronic HCV-4 Infection
    AU  - Hany Awadallah
    AU  - Ayman Mortada
    AU  - Reham Ezzat Al Swaff
    AU  - Ahmed Jomaa
    AU  - Fatma Ali-Eldin
    Y1  - 2017/04/15
    PY  - 2017
    N1  - https://doi.org/10.11648/j.ccr.20170102.12
    DO  - 10.11648/j.ccr.20170102.12
    T2  - Cardiology and Cardiovascular Research
    JF  - Cardiology and Cardiovascular Research
    JO  - Cardiology and Cardiovascular Research
    SP  - 32
    EP  - 38
    PB  - Science Publishing Group
    SN  - 2578-8914
    UR  - https://doi.org/10.11648/j.ccr.20170102.12
    AB  - Patients with chronic hepatitis C virus infection are more likely to have systemic hypertension, in addition to insulin resistance and diabetes. The present study aimed to evaluate the association between systemic hypertension and chronic HCV-4 infection among Egyptian patients. This cross-sectional study evaluated the existence of systemic hypertension among one thousand adult Egyptian subjects (500 patients with chronic HCV-4 infection versus 500 non infected subjects who served as a control group). Prevalence of systemic hypertension was significantly higher among patients with chronic HCV-4 infection (38.8%) than among the controls (21.8%) (P=0.001). 30.3% of all hypertensive patients were not aware of their illness; the rate of non-awareness among hypertensive patients with chronic HCV-4 infection was 22.68% while that of non infected subjects was 44.04% (p < 0.05). A statistically significant higher rate of systemic hypertension was found among diabetic patients. In conclusion, significant association exists between chronic HCV-4 infection and systemic hypertension especially among diabetic patients. Patients with chronic HCV infection are more aware of their systemic hypertension than non infected subjects.
    VL  - 1
    IS  - 2
    ER  - 

    Copy | Download

  • Sections